Close
Almac
Achema middle east

News

GSK Licences COPD Drug from Empirico for $85 Million Upfront

In just a space of 24 hours, GSK, in its second pipeline-expanding deal, has gone on to license the rights to a drug for chronic obstructive pulmonary disease – COPD from Empirico, the US biotech, for $85 million, and...

KLN Named Exclusive Distributor for Siemens Healthineers Point-of-Care Testing Solutions in Hong Kong

KLN Logistics Group Limited announced a strategic partnership between its healthcare subsidiary, KLN Medical Limited (‘KLN Medical’), and global medical technology leader Siemens Healthineers AG (Stock Code SHL.DE). KLN Medical will serve as the exclusive distributor for Siemens Healthineers’...

Thermo Fisher to Acquire Clario Holdings for $8.9bn

Thermo Fisher to acquire Clario Holdings, the clinical trial data firm, for $8.9 billion in cash is in news and the same has been announced by the companies on October 29. Clario is at present held by a shareholder group...

Simtra BioPharma Expands High-Quality Sterile Injectables

One of the leading contract development and manufacturing organization – CDMO that specializes in high-quality sterile injectables, Simtra BioPharma Solutions, has made tremendous progress on a dual-continent expansion strategy in order to meet the growing global demand for intricate...

Applications of the TXA2 Rat ELISA Kit in Cardiovascular Disease Research

The heart is a muscular organ responsible for circulating blood throughout the body. It ensures oxygen-rich blood reaches every tissue and organ and removes carbon dioxide and waste products from the body. However, genetics, poor diet, sedentary lifestyle, exposure to...

5 Critical Challenges in Monoclonal Antibody Production

Monoclonal antibodies have completely revolutionized the field of modern medicine by offering targeted therapies for a range of diseases such as cancer, autoimmune disorders, and infectious diseases. In fact, the global monoclonal antibody market is projected to reach USD 494.53...

J&J To Be in Sync with Trump Administration as MFN Spreads

As the two Trump administration drug pricing deals find their place in the books and more that are likely on the way, the U.S. policy environment can very well soon stabilize for many Big Pharma companies. All this puts...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »